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Abstract
Background: The introduction of combination antiretroviral therapy (ART) has resulted in
striking reductions in HIV-related mortality. Despite increased availability of ART, children remain
a neglected population. This may be due to concerns that failure to adhere appears to be related
to continued viral replication, treatment failure and the emergence of drug-resistant strains of HIV.
This study determines the rates and factors associated with adherence to Antiretroviral (ARV)
Drug therapy in HIV-infected children who were receiving Highly Active Antiretroviral Therapy
(HAART) in Addis Ababa, Ethiopia in 2008.
Methods: A cross-sectional study was conducted in five hospitals in Addis Ababa from February
18 – April 28, 2008. The study population entailed parents/caretaker and index children who were
following ART in the health facilities. A structured questionnaire was used for data collection.
Results: A total of 390 children respondents were included in the study with a response rate of
91%. The majority, equaling 205 (52.6%) of the children, were greater than 9 years of age. Fifty five
percent of the children were girls. A total of 339 children (86.9%) as reported by caregivers were
adherent to antiretroviral drugs for the past 7 days before the interview. Numerous variables were
found to be significantly associated with adherence: children whose parents did not pay a fee for
treatment [OR = 0.39 (95%CI: 0.16, 0.92)], children who had ever received any nutritional support
from the clinic [OR = 0.34 (95%CI: 0.14, 0.79)] were less likely to adhere. Whereas children who
took co-trimoxazole medication/syrup besides ARVs [OR = 3.65 (95%CI: 1.24, 10.74)], children
who did not know their sero-status [OR = 2.53 (95%CI: 1.24, 5.19)] and children who were not
aware of their caregiver's health problem [OR = 2.45 (95%CI: 1.25, 4.81)] were more likely to
adhere than their counterparts.
Conclusion: Adherence to HAART in children in Addis Ababa was higher than other similar
setups. However, there are still significant numbers of children who are non-adherent to HAART.
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Background
HIV/AIDS is one of the most destructive epidemics the
world has ever witnessed. In 2007 an estimated 33.2 mil-
lion people were living with HIV (PLHIV) worldwide,
while 2.5 million of these people were children under 15
years old. Furthermore, 420,000 Children under 15 years
were newly infected with HIV in 2007. Nearly 90% of all
HIV-positive children live in sub-Saharan Africa [1].
About 780,000 were estimated to be in need of antiretro-
viral therapy [2]. The most efficient and cost effective way
to tackle pediatric HIV globally is to reduce Mother to
Children Transmission (MTCT). However, every day there
are nearly 1200 new infections in children under 15 years
of age with more than 90% of these occurring in the devel-
oping world and most being associated with MTCT [3].
Trials in the United States and Western Europe have dem-
onstrated that HAART is effective in suppressing HIV viral
replication and reversing immunodeficiency in children
[4,5]. The result has been a reduction in pediatric hospital
admissions and a decrease in morbidity and mortality due
to HIV/AIDS [6-9]. The introduction of combination ART
including protease inhibitors has resulted in striking
reductions in HIV-related mortality [10-12]. However,
these therapeutic regimens are very complex, often requir-
ing that patients take numerous pills multiple times a day
with specific timing and food restrictions or requirements.
Failure to adhere very closely to the regimens appears to
be related to continued viral replication, treatment failure
and the emergence of drug-resistant strains of HIV [13-
15].
In sub-Saharan Africa, AIDS has become one of the lead-
ing causes of mortality among children under the age of
five years. Despite increased availability of ART, children
remain a neglected population group [16]. However,
many factors can affect the ability of HAART to suppress
viral replication, including low potency of one of the
drugs in the combination, viral resistance, inadequate
drug exposure and inadequate adherence to therapy. The
major factor determining the Success of HAART is sustain-
able and optimum adherence to therapy [17] as poor
adherence increases the risk of virologic failure and viral
resistance [18]. Therefore this study determines the rates
and factors associated with adherence to ARV therapy
among HIV-infected children who are receiving HAART in
Addis Ababa, Ethiopia.
Methods
Study area
The study was conducted in selected hospitals in Addis
Ababa city, the Capital City of the Federal Democratic
Republic of Ethiopia. As of August 2007 the total number
of children on ART in Ethiopia was 3865 [19]. The study
was carried out in selected ART units in Addis Ababa Hos-
pitals including Black Lion, St. Peter, Yekatit 12, Zewditu,
and ALERT Hospitals. Among these, Black Lion Hospital
is a teaching hospital under the Federal Ministry of Educa-
tion. St. Paul Hospital is a General Specialized Hospital
under the Federal Ministry of Health. St. Peter Hospital is
a Generalized Hospital for TB treatment and they recently
opened an ART clinic for adult and children. ALERT Hos-
pital is also under the Federal Ministry of Health. Yekatit
12 and Zewditu Hospitals are under the Addis Ababa
Regional Health Bureau, known to serve most of the
patients on ART follow-up. This study was conducted
from February 18 – April 28, 2008. The study design was
a facility-based cross-sectional study.
Participants
The source populations were children who had been tak-
ing ARV and were on follow up in the ART units of the
selected hospitals during the study period. The study pop-
ulation included sampled children who had been taking
combination ARV medications who were on follow-up as
well present during the data collection period. Children
who fulfilled the following criteria were included in the
study: Receiving continuous antiretroviral therapy for the
last 12 weeks before study in the selected hospital and the
caregiver (parents or guardians) was counseled on the
importance of drug adherence and on how to recognize
common adverse drug reactions associated with antiretro-
viral drugs. The exclusion criteria were: children who were
terminally ill, age less than 3 months or greater than 14
years and a caregiver in a moribund state. The sample size
was calculated using two proportions sample size formula
using Epi Info (CDC, Atlanta, U.S.A., 2005) 6.04 statisti-
cal package. The following parameters were used to calcu-
late the sample size: proportion of adherence (P1) among
male children 33%, proportion of adherence (P2) among
female children 20% [20], 95% CI and 80% power. This
gave a sample size of 393. Adding 10% for non-response
rate, the total sample size was 433. A simple random sam-
pling technique was employed to identify the study units
using the ART unique numbers from the registration book
in each hospital.
Measurements
Data were collected by structured pre-tested questionnaire
which was adopted from different studies [9,16-18]. The
questionnaire was originally developed in English trans-
lated to Amharic and back translated to English by a trans-
lator who was blind to the original questionnaire. The
content of the questionnaire included: socio-demo-
graphic characteristics (age of the child, sex of the child,
age of the caregiver, ethnicity, educational status, occupa-
tional status of the caregiver); socio-economics conditions
(monthly income, financial support for the child, grant
for the child); medication related factors; health care
delivery systems related factors including access to care,
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disclosure status of the children; perception related to the
services, diagnosis, referral and treatment, and medication
administration. Attitude was measured using a previously
determined scale on attitude [16] where a set of 12 Likert
scale questions addressed the attitude of the caregiver
towards adherence. The independent variables were
socio-economic status, socio-demographic factor, clinical
characteristics (clinical stage of the children (World
Health Organization stage I-IV) and CD4 cells/mm3
count of the children), perception related to the services
(diagnosis, referral and treatment), medication adminis-
tration including dosing. The dependent variable was car-
egivers' report adherence to ART in the past 7 days. A total
of three days of intensive training was given to all supervi-
sors and data collectors. The interview was conducted in
private room to create an atmosphere of empathy and
confidence. Medical charts were reviewed to collect clini-
cal and immunological markers. The principal investiga-
tor and three general practitioners supervised the data
collection process.
Data analysis and processing
Data entry and analyses were carried out using SPSS ver-
sion 12.0.1 statistical packages. First, descriptive statistics
were carried out to explore the socio-demographic charac-
teristics of the respondents, the adherence rate and clinical
characteristics of the children. To find association
between the exposure variables and adherence, bivariate
analysis was done. To control the effect of confounding
variables, stepwise logistics regression was done. Variables
which showed statistical significant association (P < 0.05)
in the bivariate analysis were included in the final model.
To ensure quality of the data, pre-testing of the question-
naire was undertaken in 5 percent of the sample size in
similar setups before the actual data collection took place.
The final version of the questionnaire was used for the
data collection. The overall activity was monitored by the
principal investigator. There were strict supervisions dur-
ing data collection. One trained data clerk entered and
cleaned the data.
Operational Definitions
Adherence – a child is said to be adherent if he/she missed
no more than one dose (took more than 95% of the pre-
scribed doses correctly) for one week prior to the study.
Primary caregiver – a person who has consistently
assumed responsibility for the housing, health, or safety
of the child (individuals who administered the child med-
ication daily and bringing the child for clinic appoint-
ments).
Attitude – twelve Likert Scale attitude questions were pre-
sented to respondents. One variable was computed using
the sum of the 12 questions. If respondents score more
than 36, they were labeled as having favorable attitude.
Unfavorable attitude was considered as a score less than
36.
Ethical consideration
Ethical clearance was obtained from Institutional Ethical
Review Committee of Jimma University and Ethical clear-
ance Committee of Addis Ababa Health Bureau. An offi-
cial letter of co-operation from the above organization
and Federal Ministry of Health (FMOH) was given to
respective hospitals. Caregivers gave verbal informed con-
sent for participating in the study.
Results
Socio-demographic and economic characteristics
A total of 390 children respondents were included in the
study with response rate of 91%. The majority 205
(52.6%) of the children was above 9 years. The median
age of the children was 9 years (range: 1 to 14 years). Fifty
five percent of the children were girls. Most of the study
participants were Amhara (53%) and Oromo (24%) by
ethnicity. A majority (76.2%) of the caregivers were ortho-
dox by religion. Concerning the educational status of the
caregiver, 176, or 45.1%, were in primary school. Regard-
ing occupation, 103 (26.4%) were daily laborers and 80
(20.5%) were working as a government employee. One
hundred seventy four (44.6%) of the caregivers were mar-
ried and 138 (35.4%) were widowed. Three hundred sev-
enty (94.9%) of the respondents were the primary
caregivers of the child. Two hundred forty (61.5%) of the
primary caregivers were biological parents of the children.
The remaining were non-biological parents. The study
subjects were on HAART for a mean and median duration
of 20 and 24 months (12 to 48 month). One hundred
sixty-two (67.5%) of the biological parents serving as a
caregiver were the biological mother of child (See table 1).
A large proportion of caregivers, equaling 277 (71%),
mentioned that no one had helped the child financially.
Fathers (6.4%) and local NGOs (6.4%) were responsible
to help some of the children. Of the 390 caregivers, 21.8
percent received a childcare grant. About 277 (71.4%) of
the respondents had household income levels below 500
Eth. Birr per month (Exchange rate 1 USD = 9.6 Ethiopian
Birr (ETB)). (Data not presented)
Clinical Markers of the Participants
Most of the children (193 [49.5%]) were in stage III based
on WHO classification. The mean and median initial CD4
count were 273.28 cells/mm3 and 203.00 cells/mm3
respectively and 576.92 cells/mm3 and 497.50 cells/mm3
were the latest CD4 counts. One hundred ninety-four
(49.7%) of the children had a CD4 count of <200 cells/
mm3 at the start of the treatment. A similar number of
children had CD4 count of > = 500 cells/mm3. One hun-
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Table 1: Demographic and social characteristics of caregiver and children in Addis Ababa, Ethiopia [N = 390], April 2008
Variable Frequency(percentage) p-value
Adherent Non-adherent
Age (years) 0.672
<3 14(4.1) 1(2)
3–5 39(11.5) 4(7.8)
6–8 111(32.7) 16(31.4)
> = 9 175(51.6) 30(58.8)
Sex of the child 0.347
Boy 149(44) 26(51)
Girl 190(56) 25(49)
Religion of the caregiver 0.607
Orthodox 261(77) 36(70.6)
Catholic 18(5.3) 3(5.9)
Protestant 37(10.9) 8(15.7)
Muslim 16(4.7) 2(3.9)
Others * 7 (2.1) 2(3.9)
Occupational status of the caregiver 0.343
Farmer 0(0) 4(7.8)
Merchant 50(14.7) 5(9.8)
Governmental employee 52(15.3) 6(11.8)
NGO employee 28(8.3) 1(2)
Day laborer 84(24.8) 19(37.3)
Jobless/house made 71(20.9) 9(17.6)
Others£ 54(15.9) 7(13.7)
Marital status of the caregiver 0.198
Single 36(10.6) 2(3.9)
Married 154(45.4) 20(39.2)
Divorced 32(9.4) 8(15.7)
Widowed 117(34.5) 21(41.2)
Educational status of the caregiver 0.107
Unable to read and write 75(22.1) 19(37.3)
Primary (1–8) 157(46.3) 19(37.3)
Secondary (9–12) 62(18.3) 6(11.8)
Diploma and above 45(13.3) 7(13.7)
Are you the primary caregiver 0.083
Yes 320(94.4) 51(100)
No 19(5.6) 0(0)
Who is the primary caregiver responsible for the child? 0.296
Biological parents 212(62.5) 28(54.9)
Non-biological parents 127(37.5) 23(45.1)
Child HIV status disclosure 0.001
Yes 51(15) 17(33.3)
No 288(85) 34(66.7)
Health care Provider's estimate of adherence 0.001
Good 295(87) 32(62.7)
Fair 9(11.5) 11(21.6)
Poor 5(1.5) 8(15.7)
Monthly income in ETB 0.154
<105 235(69.7) 42(82.4)
106–150 45(13.4) 5(9.8)
151–262 57(16.9) 4(7.8)
Do you know when the child start treatment 0.559
Yes 296(87.3) 46(90.2)
No 43(12.7) 5(9.8)
Duration of treatment in months 0.278
≤ 12 100(29.5) 21(41.2)
13–24 185(54.6) 21(41.2)
24–36 44(13) 8(15.7)
≥ 36 10(2.9) 1(2)
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dred eleven children (30%) had been taking the Stavu-
dine (d4T)/Lamivudine (3TC)/Nevirapine (NVP) based
regimen. About 115 (27%) of the children were taking
Zidovudine (AZT)/3TC/NVP and AZT/3TC/(Efavirenz)
EFV for each regimen (See Table 2).
Knowledge, Perceptions and Attitude about ARV 
Medications Administration
Seventy percent of the participants (caregivers) had
received information about ARV treatment from the hos-
pitals (Government and Private). Overall, the participant
attitudes on administration of ARV medication to the chil-
dren were favorable in 380 (97.4%) of the respondents
with the 12 points Liker scale instrument (See Table 1).
Medication Administrations and Adherence
Caregivers used different mechanisms as reminders to
administer medications on time; the most common
reminder was cellular phone alarm systems (25.4%) fol-
lowed by watches/clocks (46.4%). A total of 51 children
(13.1%) omitted at least one dose of antiretroviral drugs
in the past 7 days before the survey (See Table 3). For
those who missed a dose or more in the last 7 days, the
common reasons were lack of medication (27.5%), child
slept (25.5%) and forgetfulness to give the drugs (23.5%)
(See Figure 1).
Factors Associated With Pediatric Adherence to 
Antiretroviral Therapy
After controlling the effects of other variables, five varia-
bles were found to be significantly associated with adher-
ence to ART in children: As shown in Table 4, children
whose parents did not pay a fee for treatment were 61.3%
less likely to adhere for ART than those who paid for their
medication [OR = 0.39 (95%CI: 0.16, 0.92)]. Similarly,
children who had ever received any nutritional support
from the clinic [PEM scheme, etc.] were 66.3% less likely
to adhere to ART than those who did not get the nutri-
tional support [OR = 0.34 (95%CI: 0.14, 0.79)]. Children
who took co-trimoxazole medication/syrup besides ARVs
Care givers Attitude about Child ART 0.770
Favorable 330(97.3) 50(98)
Unfavorable 9(2.7) 1(2)
Others *--
Local, Jehovah witness
Others£ – secretary, cashier, carpenter
Exchange rate 1 USD = 9.6 Ethiopian Birr (ETB).
Table 1: Demographic and social characteristics of caregiver and children in Addis Ababa, Ethiopia [N = 390], April 2008 (Continued)
Table 2: Clinical markers of HIV infected children in Addis Ababa, Ethiopia, [N = 390] April 2008
Variable Frequency(percentage) p-value
adherent Non-adherent
WHO Clinical stage of HIV disease 0.226
Stage I 14(4.13) 1(2)
Stage II 102(30.1) 9(17.6)
Stage III 163(48.07) 30(58.8)
Stage IV 60(17.7) 11(21.6)
CD4 counts at start of treatment 0.377
<200 164(48.4) 30(58.8)
200–499 131(38.6) 16(31.4)
> = 500 44(13) 5(9.8)
Current CD4 count 0.073
<200 45(13.3) 12(23.5)
200–499 119(35.1) 20(39.2)
> = 500 175(51.6) 19(37.3)
Regimen recommended 0.105
4a = d4T/3TC/NVP 103(30.4) 16(31.4)
4b = d4T/3TC/EFV 53(15.6) 9(17.6)
4c = AZT/3TC/NVP 97(28.6) 7(13.7)
4d = AZT/3TC/EFV 86(25.4) 19(37.3)
d4T = Stavudine, 3TC = Lamivudine, NVP = Nevirapine, AZT = Zidovudine, EFV = Efavirenz
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were 3.64 times more likely to adhere than those who did
not take the co-trimoxazole [OR = 3.65 (95%CI: 1.24,
10.74)]. Children who did not know their sero-status
were 2.53 times more likely to adhere for the treatment of
ARV than children who did know their sero-status [OR =
2.53 (95%CI: 1.24, 5.19)]. Children who were not aware
of their caregiver's health problem were 2.44 times more
likely to adhere than children who had perceived aware-
ness about the illness of the caregiver [OR = 2.45 (95%CI:
1.25, 4.81)].
Discussion
This paper tries to examine the different variables associ-
ated with child adherence to antiretroviral therapy for in
Ethiopia. Clinical record review, immunological markers
and psychological and medication-related factors were
assessed along with the caregiver characteristics to deter-
mine the predictors of adherence.
Adherence is a special issue in pediatrics not only because
of social situations but also because many of the drugs are
not child friendly [21]. This study found an estimated
prevalence of caregivers' report of adherence to antiretro-
viral treatment to be 93.1% in 3 days and 86.9% in a 7-
day recall period. Adherence rate in other studies ranged
from 26% to 97% [22-30]. The possible explanations for
the greater adherence in our study might be that the
majority of the children started ART recently, the children
were taking medication with a twice-daily dosing sched-
ule, or the children and caregivers were given strict adher-
ence counseling sessions before starting ART in the
Table 3: Caregivers' report adherence rate of HAART among 
children in Addis Ababa, Ethiopia, April 2008
Days Adherent No(%) Non adherent No (%) Total
Today 383(98.2%) 7(1.8%) 390(100%)
Yesterday 378(96.9%) 12(3.1%) 390(100%)
Past 3 days 363(93.1%) 27(6.9%) 390(100%)
Past 7 days 339(86.9%) 51(13.1%) 390(100%)
Reasons for missing dose in children who were on HAART in Addis Ababa, Ethiopia, April 2008Figure 1
Reasons for missing dose in children who were on HAART in Addis Ababa, Ethiopia, April 2008.
27.5
25.5
23.5
9.8
5.9
5.9
2
0 5 10 15 20 25 30
Drug run out at home
Child slept
Caregiver’s forgetfulness
Caregiver do not believe on drug
She/he became depressed
Transportation problem
She/he was ill at that time
Percent
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hospitals and the majority of caregivers (97.4%) had a
favorable attitude toward administration of ARV to chil-
dren.
In this study children whose caregivers paid for medica-
tion before ART were more adherer than those who did
not pay. Hence, people tend to give value for their health
when they spend money for treatment of their illness.
Similarly, studies [31,32] revealed that costs have an
implication for adherence. However, it varies at different
stages of HIV infection, such that patient's who present
late, especially if more immuno-suppressed, use more
services at greater cost than those who are less immuno-
suppressed. An increasing adherence rate was observed in
children with more advanced HIV [33]. Again, a similar
pattern has been reported in adults [34,35].
One of the entry points that complicated the issue of
adherence for HIV infected children is the issue of disclo-
sure of HIV status to the child [36]. Studies showed that
complete parental disclosure helps to motivate HIV-
infected children to adhere to their daily medical regimen.
It enables children to understand HIV infection and to
make sense of disease-related experiences and the impor-
tance of adherence [37,38]. In this study, however non-
disclosure had a significant relevance for adherence to the
recommended regimen. It is consistent with other studies,
which showed no effect of disclosure on adherence to ART
[22,39], which is also the case in the Multicenter National
Study in Italy [33].
Interestingly, those who took co-trimoxazole prophylaxis
besides taking ARV medications were more likely to
adhere than those who did not use the treatment. Proph-
ylaxis is probably at least as important as ART in prevent-
ing the onset of AIDS in children [40,41]. It is also
supported by a study which revealed daily co-trimoxazole
lays the groundwork for medication adherence by the
patient and the establishment of reliable drug distribution
systems [42]. Nutrition interventions can help to opti-
mize the benefits of ARVs and may increase compliance
with treatment regimens, both of which are essential to
prolonging the Lives of People Living with HIV (PLHIV)
and preventing the MTCT [43]. However; in our study
receiving nutritional support from the clinic had an
inverse relationship with adherence to ART therapy. In
contrast to our finding, it is reported that one of the signif-
icant barriers to adherence was insufficient food and
patients reported that lack of food prevented or delayed
them taking their medication [44]. Provision of food and
micronutrients has been shown to improve outcomes [45-
47]. In a South African study, many families spend more
than 50% of their household income on food and food
production and wage earnings were adversely affected
when an adult has AIDS [48]. In the same line, poverty
factors such as food insecurity and user fees for medical
care, posed more significant barriers to adhering to long-
term therapy than a patient's individual behavior. In a
pilot program in Zambia on nutritional supplementation
for food insecure patients on ART, it was shown that
patients receiving food were on average 2.4 days late for
their pharmacy appointments, whereas patients not
receiving food were on average 3.4 days late each month.
Patients receiving food were significantly adhered to phar-
macy visits than patients not receiving food [49]. Surpris-
ingly, in our study, adherence rates were significantly
Table 4: Independent predictors of adherence to ART among children in Addis Ababa, Ethiopia (n = 390), April 2008
Variable Adherence Status Crude OR (95%CI) P-value Adjusted OR (95%CI) P-value
Non-adherent Adherent
Medication charge for child treatment before ARV 
intake
YES 7 104 1.00 0.016 1.00
NO 44 235 0.36(0.16,0.83) 0.39(0.16,0.92) 0.033
Co-trimoxazole intake beside ARV
Yes 44 324 3.44(1.33,8.93) 0.011 3.65(1.24,10.74)
No 7 15 1.00 1.00 0.019
Perceived awareness of the child on health problem 
of caregiver
Yes 20 63 1.00 1.00 0.009
No 31 276 2.826(1.51,5.28) 0.001 2.45(1.25,4.81)
The child knows his/her sero-status
Yes 17 51 1.00 0.002 1.00 0.011
No 34 288 2.824(1.47,5.43) 2.53(1.24,5.19)
Received nutritional support from the clinic
Yes 44 216 0.28(0.12,0.64) 0.003 0.34(0.14,0.79) 0.013
No 7 123 1.00 1.00
OR = Odds Ratio, CI = Confidence Interval
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lower in those who received nutritional support than in
those who did not. The inverse relationship between
adherence to HAART and nutritional support is somewhat
worrisome and needs to be investigated further in order to
plan interventions in HIV infected children.
This study had some limitations and strengths. The main
limitation of this study was recall bias. There is no gold
standard assessment of adherence. In this study, adher-
ence was measured using self-reports from the caregivers,
which tends to overestimate the prevalence of adherence.
The cross-sectional nature may hinder the ability to
exactly identify the predictor of adherence, unlike a longi-
tudinal design. Caregivers might be prone to social desir-
ability bias responding inappropriately to the counselors.
Adherence classification cutoff points may not be perfect
in different setups to compare and contrast the finding.
Despite the above limitations, the study had several
strengths, including using a relatively large sample size,
inclusion of several sites, use of more than one method of
adherence assessment and inclusion of several variables.
Conclusion
From this research finding, it is concluded that caregivers'
report adherence to HAART in children in Addis Ababa
was 93% in the past 3 days and 87% in the past 7 days
before the date of interview and it is acceptably higher
than other similar setups. Children whose parents did not
pay a fee for treatment, children who had ever received
any nutritional support from the clinic were less likely to
adhere. While children who took co-trimoxazole besides
ARVs, children who did not know their sero-status and
children who were not aware of their caregiver's health
problem were more likely to adhere than their counter-
parts. To encourage child adherence to ART, using co-tri-
moxazole prophylaxis along with the delivery of ART
might help. Further research is recommended to explore
the relationship between disclosure and adherence and
the effect of nutritional support on adherence.
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